121 related articles for article (PubMed ID: 24490956)
1. Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Dorn J; Beaufort N; Schmitt M; Diamandis EP; Goettig P; Magdolen V
Crit Rev Clin Lab Sci; 2014 Apr; 51(2):63-84. PubMed ID: 24490956
[TBL] [Abstract][Full Text] [Related]
2. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
[TBL] [Abstract][Full Text] [Related]
3. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
4. Roles and regulation of membrane-associated serine proteases.
Qiu D; Owen K; Gray K; Bass R; Ellis V
Biochem Soc Trans; 2007 Jun; 35(Pt 3):583-7. PubMed ID: 17511657
[TBL] [Abstract][Full Text] [Related]
5. Cell surface-anchored serine proteases in cancer progression and metastasis.
Martin CE; List K
Cancer Metastasis Rev; 2019 Sep; 38(3):357-387. PubMed ID: 31529338
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
7. The roles of proteases in prostate cancer.
Koistinen H; Kovanen RM; Hollenberg MD; Dufour A; Radisky ES; Stenman UH; Batra J; Clements J; Hooper JD; Diamandis E; Schilling O; Rannikko A; Mirtti T
IUBMB Life; 2023 Jun; 75(6):493-513. PubMed ID: 36598826
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?
Tan OL; Whitbread AK; Clements JA; Dong Y
Biol Chem; 2006 Jun; 387(6):697-705. PubMed ID: 16800730
[TBL] [Abstract][Full Text] [Related]
9. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
10. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E
Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
12. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
13. Interdependence of kallikrein-related peptidases in proteolytic networks.
Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
[TBL] [Abstract][Full Text] [Related]
14. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
15. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
[TBL] [Abstract][Full Text] [Related]
16. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
17. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
18. Kallikrein-related peptidases in cancers of gastrointestinal tract: an inside view of their role and clinical significance.
Linardoutsos D; Gazouli M; Machairas A; Bramis I; Zografos GC
J BUON; 2014; 19(1):53-9. PubMed ID: 24659643
[TBL] [Abstract][Full Text] [Related]
19. Human tissue kallikrein gene family: a rich source of novel disease biomarkers.
Diamandis EP; Yousef GM
Expert Rev Mol Diagn; 2001 Jul; 1(2):182-90. PubMed ID: 11901813
[TBL] [Abstract][Full Text] [Related]
20. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2010 May; 391(5):505-11. PubMed ID: 20302518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
